Drugs / polyvalent vaccine-KLH conjugate
last change Jul 2022 re-read 2 minutes ago

polyvalent vaccine-KLH conjugate

Vaccine

Developed for
fallopian tube cancer · ovarian cancer · peritoneum cancer
Investigated by
Genentech, Inc. · Memorial Sloan Kettering Cancer Center

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT01223235 Oct 2010 → Sep 2017 fallopian tube cancer, ovarian cancer, peritoneum cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as polyvalent vaccine-KLH conjugate ClinicalTrials.gov intervention name — accepted as the source's own label NCT01223235
Modality Vaccine “polyvalent antigen-KLH plus OPT-821 vaccine construct” PMID 35779095 Jul 2022